Glaukos Corporation GKOS

GKOS Company Overview

Glaukos Corporation is a medical technology company focused on the development and commercialization of ophthalmic therapies, primarily for the treatment of glaucoma and corneal disorders. The company operates within the ophthalmic medical device and eye care therapeutics industries, with a core emphasis on micro-invasive surgical solutions and biologic-based corneal health products. Glaukos is best known for pioneering micro-invasive glaucoma surgery (MIGS), offering alternatives to traditional glaucoma surgeries that aim to reduce intraocular pressure with fewer complications.

The company’s primary revenue drivers are implantable glaucoma devices and pharmaceutical-grade corneal health products sold to ophthalmologists, ambulatory surgery centers, and hospitals. Glaukos differentiates itself through first-mover advantage in MIGS, a strong intellectual property portfolio, and a strategy that combines device-based and biologic approaches to chronic eye disease management. Founded in 1998, Glaukos evolved from a single-product device innovator into a diversified ophthalmic platform company following regulatory approvals, expanded product lines, and strategic acquisitions in corneal health.